These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 3263545

  • 1. Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2.
    Barnavon Y, Iwaki H, Bash JA, Brettschneider F, Hilsenbeck S, Darnell E, Wallack MK.
    J Surg Res; 1988 Dec; 45(6):523-30. PubMed ID: 3263545
    [Abstract] [Full Text] [Related]

  • 2. Vaccinia colon oncolysate immunotherapy for murine hepatic metastases can be modulated with low-dose interleukin-2. Third place winner: Conrad Jobst Award.
    Barnavon Y, Iwaki H, Bash JA, Wallack MK.
    Am Surg; 1988 Dec; 54(12):696-701. PubMed ID: 3264127
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma.
    Tanaka N, Sivanandham M, Wallack MK.
    J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):283-93. PubMed ID: 7881637
    [Abstract] [Full Text] [Related]

  • 4. Vaccinia virus-infected C-C36 colon tumor cell lysates stimulate cellular responses in vitro and protect syngeneic Balb/c mice from tumor cell challenge.
    Iwaki H, Barnavon Y, Bash JA, Wallack MK.
    J Surg Oncol; 1989 Feb; 40(2):90-6. PubMed ID: 2915544
    [Abstract] [Full Text] [Related]

  • 5. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.
    Arroyo PJ, Bash JA, Wallack MK.
    Cancer Immunol Immunother; 1990 Feb; 31(5):305-11. PubMed ID: 2376048
    [Abstract] [Full Text] [Related]

  • 6. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice.
    Sivanandham M, Shaw P, Bernik SF, Paoletti E, Wallack MK.
    Cancer Immunol Immunother; 1998 Jul; 46(5):261-7. PubMed ID: 9690454
    [Abstract] [Full Text] [Related]

  • 7. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.
    Cameron RB, Spiess PJ, Rosenberg SA.
    J Exp Med; 1990 Jan 01; 171(1):249-63. PubMed ID: 2295878
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.
    Sivanandham M, Scoggin SD, Tanaka N, Wallack MK.
    Cancer Immunol Immunother; 1994 Apr 01; 38(4):259-64. PubMed ID: 8168121
    [Abstract] [Full Text] [Related]

  • 9. Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases.
    Fujiwara T, Sakagami K, Matsuoka J, Shiozaki S, Uchida S, Fujioka K, Takada Y, Onoda T, Orita K.
    Cancer Res; 1990 Nov 01; 50(21):7003-7. PubMed ID: 2208166
    [Abstract] [Full Text] [Related]

  • 10. Recombinant vaccinia interleukin-2-infected tumor cell vaccines in immunotherapy of murine colon adenocarcinoma.
    Bash JA.
    J Immunother Emphasis Tumor Immunol; 1993 Nov 01; 14(4):269-72. PubMed ID: 8280707
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R, Rosenberg SA.
    Cancer Res; 1985 Aug 01; 45(8):3735-41. PubMed ID: 3893689
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
    Jack AM, Aydin N, Montenegro G, Alam K, Wallack M.
    J Surg Res; 2007 May 15; 139(2):164-9. PubMed ID: 17275030
    [Abstract] [Full Text] [Related]

  • 16. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R, Rosenberg SA.
    J Immunol; 1985 Dec 15; 135(6):4273-80. PubMed ID: 3877766
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
    Rosenberg SA, Spiess P, Lafreniere R.
    Science; 1986 Sep 19; 233(4770):1318-21. PubMed ID: 3489291
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer.
    Sivanandham M, Stavropoulos CI, Kim EM, Mancke B, Wallack MK.
    Cancer Immunol Immunother; 2002 Apr 19; 51(2):63-71. PubMed ID: 11904730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.